Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Atopic Dermatitis: New and Emerging Topical Therapies
Description
The presentation discusses new and emerging topical therapies for atopic dermatitis, emphasizing the importance of topical treatments in patient care. Traditional treatments like topical corticosteroids, calcium neuron inhibitors, and non-steroidal agents are reviewed, with a focus on recent developments. Topical ruxolitinib has been shown to outperform traditional corticosteroids in clinical trials, demonstrating effectiveness in reducing itch and inflammation. New treatments like tapinarof, which targets specific cytokines, and riflumilast, a PDE4 inhibitor, have also shown promise in studies for patients aged 2 and older. The presentation highlights the complex perceptions around topical corticosteroids, particularly among patients worried about side effects, and emphasizes the need for effective education on their use. Furthermore, it acknowledges the evolving landscape of dermatological care with proactive regimens and new formulations being explored. The talk calls for a comprehensive understanding of body surface area for dosing as well as the acknowledgment of the burdens placed on families managing atopic dermatitis. As new treatments become available, the presentation emphasizes the continuous need for effective management strategies and education regarding topical therapies to ensure optimal patient outcomes.
View moreConclusions
- Topical therapy remains essential in managing atopic dermatitis, offering a blend of excellent skincare, anti-inflammatories, and innovative non-steroidal agents.
- Emerging treatments like Ruxolitinib, Roflumilast, and Tapinarof are showing promise for pediatric patients with atopic dermatitis.
- Ruxolitinib is effective in quickly relieving itch and maintaining disease control over long periods, with high rates of efficacy in controlled studies.
- Roflumilast and Tapinarof have been found to be effective for long-term maintenance, with low rates of discontinuation and good safety profiles.
- There is a significant need for effective communication about the safety and efficacy of topical corticosteroids to combat misinformation.
- Innovative approaches such as the Topical Volume Calculator can aid healthcare providers in managing topical medication use better.
- Proactive, longer-term treatment strategies may lead to better outcomes in patients with atopic dermatitis.
- Future research is essential to discover new therapeutic options and validate the benefits of current therapies in diverse patient populations.
- Kleinman E, Laborada J, Metterle L, Eichenfield LF. Am J Clin Dermatol. 2022 Sep;23(5):595-603. doi: 10.1007/s40257-022-00712-0
- Jo SY, Lee C-H, Jung W-J, Kim S-W, Hwang Y-H. Common features of atopic dermatitis with hypoproteinemia Vol.61, Korean Journal of Pediatrics. Korean Pediatric Society; 2018. p. 348-54
- Lee C et al. Clinical significance of atopic dermatitis with hypoalbuminemia in Korean children. Iranian J of Pediatrics;
- Papp K, et al. RAD June 2021 Virtual Conference, #511. Sponsored by Incyte Corporation
- Kim BS et al. J Allergy Clin Immunol 202;145:572-582
- Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF et al. J Am Acad Dermatol 2021 Oct:85:4:863-72
- Leung DYM, et al. Ann Allergy Asthma Immunol. 2022;S1081-1206(22)02048-8
- Eichenfield L, et al. EADV 2023, D1T01.1G. Sponsored by Incyte Corporation.
- Silverberg JI, et al. EADV 2023, D1T01.1G
- Paller AS, et al. Winter Clinical Miami 2023. Sponsored by Dermavant Sciences, Inc.